Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection.
Mice mounting an acute phase response, induced by sterile inflammation after a single s.c. injection of casein 24 h beforehand, were remarkably protected against lethal infection with Gram-positive or Gram-negative bacteria. This was associated with enhanced early clearance of bacteremia, greater phagocytosis and oxidative burst responses by neutrophils, and enhanced recruitment of neutrophils into tissues compared with control, nonacute phase mice. Casein-induced inflammation was also associated with increased concentrations of G-CSF in serum, and administration of neutralizing Ab to this cytokine completely abrogated protection against Escherichia coli infection after casein pretreatment. Injection of recombinant murine G-CSF between 3 and 24 h before infection conferred the same protection as casein injection. In contrast, the casein-induced acute phase response affected neither serum values of TNF-alpha, IL-1 beta, or IL-6 after E. coli infection nor susceptibility to LPS toxicity. Furthermore, protection against infection was unaffected in IL-1R knockout mice, which have deficient acute phase plasma protein responses, or after nonspecific inhibition of acute phase protein synthesis by D-galactosamine or specific depletion of complement C3 by cobra venom factor. Increased production of G-CSF in the acute phase response is thus a key physiological component of host defense, and pretreatment with G-CSF to prevent bacterial infection in at-risk patients now merits further study, especially in view of increasing bacterial resistance to antibiotics.
Noursadeghi
Mahdad
M
Center for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, London, United Kingdom.
Bickerstaff
Maria C M
MC
Herbert
Jeff
J
Moyes
David
D
Cohen
Jonathan
J
Pepys
Mark B
MB
D000209:Acute-Phase Proteins / Q000096:biosynthesis / Q000494:pharmacology / Q000502:physiology; D000210:Acute-Phase Reaction / Q000276:immunology* / Q000382:microbiology; D000818:Animals; D019138:Antibodies, Blocking / Q000008:administration & dosage; D002364:Caseins / Q000008:administration & dosage; D004927:Escherichia coli Infections / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control*; D016179:Granulocyte Colony-Stimulating Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000276:immunology / Q000502:physiology; D007113:Immunity, Innate / Q000235:genetics; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009504:Neutrophils / Q000276:immunology / Q000382:microbiology; D013290:Streptococcal Infections / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control*; D013297:Streptococcus pyogenes / Q000276:immunology
D000209:Acute-Phase Proteins; D019138:Antibodies, Blocking; D002364:Caseins; D016179:Granulocyte Colony-Stimulating Factor